Drug intelligence / Profile preview

MYO7

Development stage: Preclinical
Lead developer: Myocea
Modality: Small Molecules

Overview

MYO7 is a preclinical small molecule drug candidate from Myocea being developed for **Spinal Muscular Atrophy** with a skeletal muscle and neuromuscular junction oriented discovery rationale. The program is identified on Myocea's pipeline as an SMA asset targeting **LIM kinase** and **ROCK** signaling, implying intended modulation of cytoskeletal and muscle biology pathways relevant to SMA pathophysiology. No formal clinical data, dose, route, brand name, or more specific mechanism details have been publicly disclosed in the provided source material.

Other names: Myocea-LIM kinase-ROCK-small molecule-Spinal Muscular AtrophyMyocea LIM kinase ROCK small molecule for Spinal Muscular Atrophy

Targets

LIMK2 (LIM domain kinase 2)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on MYO7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYO7.

Explore the full profile